Centogene receives nasdaq non-compliance notice

Cambridge, mass. and rostock, germany and berlin, april 28, 2023 (globe newswire) -- centogene n.v. (nasdaq: cntg) (“centogene”, “we”, or the “company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated april 24, 2023, from the nasdaq stock market llc listing qualifications department, indicating that the company was not in compliance with the minimum bid price requirement set forth in rule 5450(a)(1) of the nasdaq listing rules since the closing bid price for the company's common shares listed on nasdaq was below us$1.00 for 30 consecutive business days (from march 10 through april 21, 2023). nasdaq rule 5450(a)(1) requires the shares to maintain a minimum bid price of us$1.00 per share, and nasdaq rule 5810(c)(3)(a) provides that failure to meet such a requirement exists when the bid price of the shares is below us$1.00 for a period of 30 consecutive business days. the nasdaq notification letter does not impact the company's listing on the nasdaq global market at this time.
CNTG Ratings Summary
CNTG Quant Ranking